2019 Medicinal Chemistry Reviews
Case History: Talzenna® (Talazoparib)—A Highly Potent, Orally Efficacious PARP Inhibitor for the Treatment of BRCA-Mutated, HER2-Negative Breast Cancer Patients.
Bing Wang, Yuqiao Shen, Leonard E. Post
Ref. n°: REV2019-ch20
You must be connected to be able to download the pdf file of this chapter.